Related Experiment Videos
Chemokine inhibition--why, when, where, which and how?
Z Johnson1, C A Power, C Weiss
1Serono Pharmaceutical Research Institute, Serono International, 14 Chemin des Aulx, CH 1228 Geneva, Switzerland.
Biochemical Society Transactions
|March 30, 2004
Summary
Chemokines, crucial for immune responses, can be targeted for treating inflammatory diseases. Inhibiting chemokine pathways offers novel therapeutic strategies for conditions like rheumatoid arthritis and multiple sclerosis.
Area of Science:
- Immunology
- Pharmacology
- Molecular Biology
Background:
- Chemokines are small cytokines that regulate immune cell movement.
- They play roles in inflammation, infection, and cancer.
- Excessive chemokine activity leads to leucocyte recruitment in inflammatory conditions.
Purpose of the Study:
- To discuss the rationale for targeting the chemokine system therapeutically.
- To introduce various points for therapeutic intervention.
- To explore innovative anti-inflammatory therapies.
Main Methods:
- Review of genetic and pharmacological studies on chemokine function.
- Discussion of therapeutic strategies targeting chemokine receptors (GPCRs) and GAG interactions.
- Exploration of intracellular signaling pathways, including PI3Kgamma.
Main Results:
- Chemokines signal through seven-transmembrane GPCRs, making them targets for small-molecule antagonists.
- Chemokine interaction with glycosaminoglycans (GAGs) is essential for cell migration and a viable therapeutic target.
- Targeting PI3Kgamma, a downstream signaling molecule, presents another small-molecule therapeutic approach.
Conclusions:
- The chemokine system provides multiple entry points for developing novel anti-inflammatory therapies.
- Targeting chemokines holds promise for treating autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and allergic contact dermatitis.